Logo
x

Search category

Subscribe Now

Fresenius Kabi

Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions

Fresenius Kabi’s Tyenne (biosimilar, tocilizumab) Receives EC’s Approval for Multiple Inflammatory and Immune Mediated Conditions

  • September 20, 2023
Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection

Fresenius Kabi Reports the Commercial Availability of Plerixafor Injection

  • August 10, 2023
Fresenius Kabi Launches Idacio (biosimilar, adalimumab) in the US for the Treatment of Chronic Autoimmune Diseases

Fresenius Kabi Launches Idacio (biosimilar, adalimumab) in the US for the Treatment of Chronic Autoimmune Diseases

  • July 4, 2023
Fresenius Kabi Launches Stimufend (biosimilar, pegfilgrastim) for Febrile Neutropenia in the US

Fresenius Kabi Launches Stimufend (biosimilar, pegfilgrastim) for Febrile Neutropenia in the US

  • February 17, 2023
Fresenius Kabi Entered into a License Agreement with Formycon to Commercialize FYB202 (biosimilar, ustekinumab)

Fresenius Kabi Entered into a License Agreement with Formycon to Commercialize FYB202 (biosimilar, ustekinumab)

  • February 2, 2023
Fresenius Kabi’s Idacio (biosimilar, adalimumab) Receives the US FDA’s Approval for the Treatment of Chronic Autoimmune Diseases

Fresenius Kabi’s Idacio (biosimilar, adalimumab) Receives the US FDA’s Approval for the Treatment of Chronic Autoimmune Diseases

  • December 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.